Inspire Investing LLC Purchases New Position in OraSure Technologies, Inc. (NASDAQ:OSUR)

Inspire Investing LLC purchased a new stake in OraSure Technologies, Inc. (NASDAQ:OSUR) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 172,287 shares of the medical instruments supplier’s stock, valued at approximately $734,000. Inspire Investing LLC owned approximately 0.23% of OraSure Technologies at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in OraSure Technologies by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 5,409,028 shares of the medical instruments supplier’s stock valued at $33,266,000 after buying an additional 99,572 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in OraSure Technologies by 8.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,906,687 shares of the medical instruments supplier’s stock valued at $32,035,000 after buying an additional 301,558 shares in the last quarter. Cannell Capital LLC boosted its stake in OraSure Technologies by 25.8% in the 4th quarter. Cannell Capital LLC now owns 3,549,050 shares of the medical instruments supplier’s stock valued at $29,102,000 after buying an additional 728,459 shares in the last quarter. Renaissance Technologies LLC boosted its stake in OraSure Technologies by 20.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,288,443 shares of the medical instruments supplier’s stock valued at $9,749,000 after buying an additional 391,100 shares in the last quarter. Finally, Acadian Asset Management LLC raised its position in OraSure Technologies by 38.1% in the 2nd quarter. Acadian Asset Management LLC now owns 2,195,582 shares of the medical instruments supplier’s stock valued at $9,349,000 after purchasing an additional 605,324 shares during the last quarter. Institutional investors and hedge funds own 93.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on OSUR shares. StockNews.com downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, August 17th. Evercore ISI lifted their price objective on OraSure Technologies from $4.50 to $5.00 and gave the company an “in-line” rating in a research report on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $6.67.

OraSure Technologies Stock Performance

Shares of OSUR opened at $4.33 on Friday. The company has a market cap of $320.24 million, a price-to-earnings ratio of 14.43 and a beta of 0.05. OraSure Technologies, Inc. has a 52-week low of $3.91 and a 52-week high of $8.45. The stock has a fifty day moving average price of $4.33 and a two-hundred day moving average price of $4.96.

OraSure Technologies (NASDAQ:OSUR) last released its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.03 earnings per share for the quarter. The company had revenue of $54.34 million during the quarter, compared to the consensus estimate of $53.35 million. OraSure Technologies had a return on equity of 9.15% and a net margin of 9.88%. As a group, research analysts predict that OraSure Technologies, Inc. will post -0.11 EPS for the current fiscal year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.